Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CSF Liquid Biopsy Based Characterization of Leptomeningeal Disease in EGFR Mutant Non-Small Cell Lung Cancer

NCT05257967 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT05257967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05257967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CSF Liquid Biopsy Based Characterization of Leptomeningeal Disease in EGFR Mutant Non-Small Cell Lung Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Recruiting
Start date
July 18, 2022
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, leptomeningeal metastasis, non small cell lung cancer